US › Healthcare

Catalyst Pharmaceuticals Inc (CPRX)

US · Healthcare · Biotechnology

$31.490.00%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$149.4M
Revenue YoY
+5.6%
Net profit
$63.7M
Profit YoY
+12.3%
EPS
$0.79
EPS estimate
$0.64
Net margin
42.7%

EPS came in at 0.79 against a street estimate of 0.64 — a beat of 23.4%.

Key statistics

Market cap
$3.85B
P/E
18.2
Forward P/E
13.0
P/B
3.81
Book value
$8.29
EPS (TTM)
$1.73
52-week high
$32.56
52-week low
$19.05
50-day MA
$31.26
200-day MA
$25.41
Beta
0.74

Analyst view

Analysts rate Catalyst Pharmaceuticals Inc a strong buy (7 buy, 0 hold, 0 sell out of 7) with an average price target of $31.67.

Shareholding

Insiders
5.57%
Institutions
90.00%

Largest institutional holders

FundStake
BlackRock Inc15.34%
Vanguard Group Inc6.89%
State Street Corp5.61%
Vanguard Capital Management, LLC4.18%
American Century Companies Inc3.38%
Deerfield Management Co3.22%
Dimensional Fund Advisors, Inc.2.80%
Bank of America Corp2.48%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Catalyst Pharmaceuticals Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.